Trevi Therapeutics Prices $150M Public Offering, Securing Funding for Haduvio Phase 3 Trials Through 2029
Summary
Trevi Therapeutics announced the pricing of its underwritten public offering, raising approximately $141.1 million to $162.4 million, which is expected to extend its cash runway through 2029 and fund pivotal Phase 3 clinical trials for Haduvio.
Key Events
-
Public Offering Priced
Trevi Therapeutics finalized its underwritten public offering, selling 11,600,000 shares of common stock at $13.00 per share. This follows the proposed offering announced on April 16, 2026.
-
Significant Capital Raise
The offering is expected to generate net proceeds of approximately $141.1 million, or $162.4 million if the underwriters fully exercise their option to purchase an additional 1,740,000 shares.
-
Extended Cash Runway
The company estimates that the proceeds, combined with existing cash, will be sufficient to fund operations through 2029, including its planned Phase 3 trials for Haduvio.
-
Clinical Development Advancement
The funding will support two pivotal Phase 3 trials for Haduvio in IPF-related chronic cough, with topline results expected in H2 2027 and H1 2028, as well as Phase 2b trials for non-IPF ILD and refractory chronic cough.
Analysis
This 8-K is highly important as it finalizes the terms of a substantial capital raise for Trevi Therapeutics, a clinical-stage biopharmaceutical company. The offering, priced at a modest discount to the current market price, is expected to generate net proceeds of $141.1 million to $162.4 million. Crucially, these funds are projected to extend the company's cash runway through 2029, enabling the advancement of its lead investigational therapy, Haduvio, through two pivotal Phase 3 trials for IPF-related chronic cough and additional Phase 2b trials. For a biotech, securing long-term funding for late-stage clinical development is a significant de-risking event, providing financial stability to pursue regulatory approvals. The detailed clinical development timelines further clarify the path forward for Haduvio.
At the time of this filing, TRVI was trading at $13.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.38 to $14.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.